A Phase 2 interventional study of GSK1070806 and Placebo in Dermatitis, Atopic, sponsored by GlaxoSmithKline. Terminated at 51 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Dermatitis, Atopic by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dermatitis, Atopic · GlaxoSmithKline.
Among the 19 studies in Dermatitis, Atopic by GlaxoSmithKline, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2024, is one of 8 in phase 2, and was the 19th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →None of the 19 studies in Dermatitis, Atopic by GlaxoSmithKline is open now. The open studies under Dermatitis, Atopic, anywhere →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2024.
This study's enrollment of 79 is close to the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 42 across the 18 interventional studies, 160 across the 1 observational. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Dermatitis, Atopic by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were previously treated with placebo in parent Study 219538 (NCT05999799) and continued on placebo subcutaneous (SC) injection in this long-term extension (LTE) study.
Drug: Placebo
Participants were previously treated with placebo in parent Study 219538 (NCT05999799) and received GSK1070806 dose level 4 SC injection in this LTE study. Dose level 4 is the highest dose level.
Drug: GSK1070806 · Drug: Placebo
Participants were previously treated with GSK1070806 dose level 1 in parent Study 219538 (NCT05999799) and maintained GSK1070806 dose level 1 SC injection in this LTE study. Dose level 1 is the lowest dose level.
Drug: GSK1070806
Participants were previously treated with GSK1070806 dose level 1 in parent Study 219538 (NCT05999799) and received GSK1070806 dose level 4 SC injection in this LTE study. Dose level 4 is the highest dose level.
Drug: GSK1070806
Participants were previously treated with GSK1070806 dose level 2 in parent Study 219538 (NCT05999799) and maintained GSK1070806 dose level 2 SC injection in this LTE study. Dose level 2 is greater than dose level 1.
Drug: GSK1070806
Participants were previously treated with GSK1070806 dose level 2 in parent Study 219538 (NCT05999799) and received GSK1070806 dose level 4 SC injection in this LTE study. Dose level 4 is the highest dose level.
Drug: GSK1070806
Participants were previously treated with GSK1070806 dose level 3 in parent Study 219538 (NCT05999799) and maintained GSK1070806 dose level 3 SC injection in this LTE study. Dose level 3 is greater than dose level 2.
Drug: GSK1070806
Participants were previously treated with GSK1070806 dose level 3 in parent Study 219538 (NCT05999799) and received GSK1070806 dose level 4 SC injection in this LTE study. Dose level 4 is the highest dose level.
Drug: GSK1070806
Participants were previously treated with GSK1070806 dose level 4 in parent Study 219538 (NCT05999799) and maintained GSK1070806 dose level 4 SC injection in this LTE study. Dose level 4 is the highest dose level.
Drug: GSK1070806
Participants will receive GSK1070806
Participants will receive Placebo
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE is an event that emerges during treatment, having been absent pre-treatment or worsens relative to the pre-treatment state. Safety Analysis Set included all assigned participants who received at least 1 dose of study intervention in this LTE study. Participants were analyzed according to the intervention they actually received.
Time frame: Up to Week 59
Number of Participants With TEAEs Leading to Permanent Discontinuation
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE is an event that emerges during treatment, having been absent pre-treatment or worsens relative to the pre-treatment state. Number of participants with TEAE leading to permanent discontinuation of GSK1070806 were reported.
Time frame: Up to Week 59
Number of Participants With Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), is a suspected transmission of any infectious agent via an authorized medicinal product, and medically important were categorized as SAE.
Time frame: Up to Week 59
Number of Participants With Treatment Emergent Adverse Events of Special Interest (TEAESI)
AESI for GSK1070806 include serious infections, opportunistic infections, serious hypersensitivity reactions, and injection site reactions (ISRs). A TEAE is an event that emerges during treatment, having been absent pre-treatment or worsens relative to the pre-treatment state.
Time frame: Up to Week 59
Number of Participants Who Achieved Investigators Global Assessment (IGA) Response (IGA Score of 0 or 1 and a Reduction of Greater Than or Equal to [>=]2 Points From Baseline) at Weeks 16, 32, and 48
IGA is a clinical tool to assess current state/severity of participant's atopic dermatitis (AtD). It is static 5-point morphological assessment of overall disease severity at time of assessment (TOA) determined by investigator, sub-investigator, or trained healthcare professional with required qualifications on scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, \& 4=severe). Higher score=high severity of disease. Data for IGA 0 or 1 responders is presented in this outcome measure. IGA 0 or 1 responders: participants whose IGA score was 'Clear' (0) or 'Almost Clear' (1) \& had reduction of \>=2 points from Baseline at each visit. 2 participants had their assigned Dose Level (DL) modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4.
Time frame: Baseline (Day 1 from the parent study), Weeks 16, 32, and 48
Number of Participants Who Achieved Reduction of Greater Than or Equal to (>=) 75 Percent (%) in Eczema Area and Severity Index (EASI) Score From Baseline at Weeks 16, 32 and 48
EASI scoring system is standardized clinical tool for assessment of extent(area) \& severity of AtD.Severity of clinical signs of AtD(erythema, induration/papulation,excoriation \& lichenification) scored separately for each of 4 body regions(head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%,1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. 2 participants had their assigned DL modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4.
Time frame: Baseline (Day 1 from the parent study), Weeks 16, 32 and 48
Number of Participants Who Achieved Reduction of >=4 Points in Peak Pruritus Numerical Rating Scale (PP-NRS) Score From Baseline at Weeks 16, 32, and 48
PP-NRS is a patient reported measure of pruritus (itch) intensity assessing worst itch (in the past 24 hours). The values were evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch. Higher scores indicated worst itch. 2 participants had their assigned dose level (DL) modified during the study, hence were included in treatment arm of the highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4. Baseline was averaged from daily values from Day -7 to Day -1 of the parent study 219538 (NCT05999799).
Time frame: Baseline (Day -7 to Day -1 from the parent study), Weeks 16, 32, and 48
Number of Participants Who Maintained IGA Response (IGA Score of 0 or 1 and a Reduction of >=2 Points From Baseline) at Weeks 16, 32, and 48
IGA is clinical tool to assess current state/severity of a participant's AtD. It measures overall disease severity at TOA(determined by investigator) using static 5-point scale(0-4): 0=clear,1=almost clear,2=mild,3=moderate,4-=severe. Higher scores indicate greater severity. IGA 0/1 responders are participants whose IGA score was 'Clear'(0) or 'Almost Clear'(1) \& had reduction of \>=2 points from Baseline at each visit. 2 participants had their assigned DL modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4. Response is considered maintained if achieved at Week 16 and sustained at later LTE timepoints; earliest maintenance timepoint was Week 32.
Time frame: Baseline (Day 1 from the parent study), Weeks 16, 32, and 48
Number of Participants Who Maintained Response of Reduction of >= 75% in EASI Score From Baseline at Weeks 16, 32, and 48
EASI: standardized clinical tool to assess extent(area) \& severity of AtD.Severity of signs (erythema,induration/papulation,excoriation \& lichenification) scored on 0-3 scale (0=absent;1=mild;2=moderate;3=severe) across 4 regions: head\&neck, upper limbs, trunk, \& lower limbs. Area score reflects % body surface area with AtD per region:0=0%,1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score=area scores(0-6) multiplied by severity scores(0-3) across regions; range: 0-72, higher scores=more severe/extensive disease. 2 participants had their assigned DL modified during study, hence included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', \& 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4. Response is considered maintained if achieved at Week 16 and sustained at later LTE timepoints; earliest maintenance timepoint was Week 32.
Time frame: Baseline (Day 1 from the parent study), Weeks 16, 32, and 48
Percent Change From Baseline (CFB) in EASI Score at Weeks 16, 32, and 48
EASI: standardized clinical tool to assess extent(area) \& severity of AtD.Severity of signs (erythema,induration/papulation,excoriation \& lichenification) scored on 0-3 scale (0=absent;1=mild;2=moderate;3=severe) across 4 regions: head\&neck, upper limbs, trunk, \& lower limbs. Area score reflects % body surface area with AtD per region:0=0%,1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score=area scores(0-6) multiplied by severity scores(0-3) across regions; range: 0-72, higher scores=more severe/extensive disease. CFB=post-dose visit value minus Baseline value (BV). Percent CFB=CFB value divided by BV \& multiplied by 100. Two participants had their assigned DL modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', \& 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4.
Time frame: Baseline (Day 1 from the parent study), Weeks 16, 32, and 48
This is long-term extension (LTE) study of parent study 219538 (NCT05999799). A total of 79 participants were enrolled in this study. This study was terminated after the parent study 219538 (NCT05999799) met pre-defined futility criteria.
| Milestone | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 13 | 3 | 10 | 9 | 5 | 1 | 8 | 27 |
| Participants with baseline peak pruritus numerical rating scale (pp-nrs) score >=4 | 3 | 13 | 2 | 11 | 8 | 6 | 1 | 8 | 22 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 13 | 3 | 10 | 9 | 5 | 1 | 8 | 27 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 1 | 3 | 4 | 1 | 1 | 0 | 7 |
| Withdrew: Study terminated by sponsor | 2 | 10 | 2 | 7 | 5 | 4 | 0 | 7 | 20 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE is an event that emerges during treatment, having been absent pre-treatment or worsens relative to the pre-treatment state. Safety Analysis Set included all assigned participants who received at least 1 dose of study intervention in this LTE study. Participants were analyzed according to the intervention they actually received.
| Participants | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 1 | 11 | 0 | 6 | 3 | 4 | 1 | 5 | 11 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE is an event that emerges during treatment, having been absent pre-treatment or worsens relative to the pre-treatment state. Number of participants with TEAE leading to permanent discontinuation of GSK1070806 were reported.
| Participants | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With TEAEs Leading to Permanent Discontinuation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An SAE is defined as any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), is a suspected transmission of any infectious agent via an authorized medicinal product, and medically important were categorized as SAE.
| Participants | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
AESI for GSK1070806 include serious infections, opportunistic infections, serious hypersensitivity reactions, and injection site reactions (ISRs). A TEAE is an event that emerges during treatment, having been absent pre-treatment or worsens relative to the pre-treatment state.
| Participants | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events of Special Interest (TEAESI) | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
IGA is a clinical tool to assess current state/severity of participant's atopic dermatitis (AtD). It is static 5-point morphological assessment of overall disease severity at time of assessment (TOA) determined by investigator, sub-investigator, or trained healthcare professional with required qualifications on scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, \& 4=severe). Higher score=high severity of disease. Data for IGA 0 or 1 responders is presented in this outcome measure. IGA 0 or 1 responders: participants whose IGA score was 'Clear' (0) or 'Almost Clear' (1) \& had reduction of \>=2 points from Baseline at each visit. 2 participants had their assigned Dose Level (DL) modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4.
| Participants | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|
| Week 16 | 2 | 4 | 1 | 1 | 4 | 1 | — | 1 | 9 |
| Week 32 | 1 | 3 | — | 1 | 4 | 2 | — | 0 | 2 |
| Week 48 | — | 1 | — | — | — | — | — | 0 | 0 |
EASI scoring system is standardized clinical tool for assessment of extent(area) \& severity of AtD.Severity of clinical signs of AtD(erythema, induration/papulation,excoriation \& lichenification) scored separately for each of 4 body regions(head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%,1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. 2 participants had their assigned DL modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4.
| Participants | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|
| Week 16 | 2 | 8 | 1 | 1 | 5 | 2 | — | 2 | 12 |
| Week 32 | 1 | 5 | — | 3 | 4 | 2 | — | 0 | 6 |
| Week 48 | — | 1 | — | — | — | — | — | 1 | 0 |
PP-NRS is a patient reported measure of pruritus (itch) intensity assessing worst itch (in the past 24 hours). The values were evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch. Higher scores indicated worst itch. 2 participants had their assigned dose level (DL) modified during the study, hence were included in treatment arm of the highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4. Baseline was averaged from daily values from Day -7 to Day -1 of the parent study 219538 (NCT05999799).
| Participants | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|
| Week 16 | 1 | 6 | 1 | 2 | 0 | 2 | — | 2 | 3 |
| Week 32 | 0 | 5 | — | 1 | 3 | 1 | — | 0 | 2 |
| Week 48 | — | 0 | — | — | — | — | — | 0 | 0 |
IGA is clinical tool to assess current state/severity of a participant's AtD. It measures overall disease severity at TOA(determined by investigator) using static 5-point scale(0-4): 0=clear,1=almost clear,2=mild,3=moderate,4-=severe. Higher scores indicate greater severity. IGA 0/1 responders are participants whose IGA score was 'Clear'(0) or 'Almost Clear'(1) \& had reduction of \>=2 points from Baseline at each visit. 2 participants had their assigned DL modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', and 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4. Response is considered maintained if achieved at Week 16 and sustained at later LTE timepoints; earliest maintenance timepoint was Week 32.
| Participants | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|
| Week 16 | 2 | 4 | 1 | 1 | 4 | 1 | — | 1 | 9 |
| Week 32 | 1 | 2 | — | — | 3 | 1 | — | — | 1 |
EASI: standardized clinical tool to assess extent(area) \& severity of AtD.Severity of signs (erythema,induration/papulation,excoriation \& lichenification) scored on 0-3 scale (0=absent;1=mild;2=moderate;3=severe) across 4 regions: head\&neck, upper limbs, trunk, \& lower limbs. Area score reflects % body surface area with AtD per region:0=0%,1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score=area scores(0-6) multiplied by severity scores(0-3) across regions; range: 0-72, higher scores=more severe/extensive disease. 2 participants had their assigned DL modified during study, hence included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', \& 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4. Response is considered maintained if achieved at Week 16 and sustained at later LTE timepoints; earliest maintenance timepoint was Week 32.
| Participants | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|
| Week 16 | 2 | 8 | 1 | 1 | 5 | 2 | — | 2 | 12 |
| Week 32 | 1 | 4 | — | — | 4 | 2 | — | 0 | 5 |
| Week 48 | — | 0 | — | — | — | — | — | — | 0 |
EASI: standardized clinical tool to assess extent(area) \& severity of AtD.Severity of signs (erythema,induration/papulation,excoriation \& lichenification) scored on 0-3 scale (0=absent;1=mild;2=moderate;3=severe) across 4 regions: head\&neck, upper limbs, trunk, \& lower limbs. Area score reflects % body surface area with AtD per region:0=0%,1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score=area scores(0-6) multiplied by severity scores(0-3) across regions; range: 0-72, higher scores=more severe/extensive disease. CFB=post-dose visit value minus Baseline value (BV). Percent CFB=CFB value divided by BV \& multiplied by 100. Two participants had their assigned DL modified during study, hence were included in treatment arm of highest dose they received (1 participant moved from 'GSK1070806 DL 1/GSK1070806 DL 1' to 'GSK1070806 DL 1/GSK1070806 DL 4', \& 1 participant moved from "GSK1070806 DL 2/GSK1070806 DL 2" to "GSK1070806 DL 2/GSK1070806 DL 4.
| Percent change | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|
| Week 16 | -98.94 ± 1.498 | -80.32 ± 17.697 | -66.76 ± 47.012 | -32.79 ± 49.095 | -95.82 ± 3.520 | -65.75 ± 22.276 | — | -52.44 ± 20.855 | -63.14 ± 36.841 |
| Week 32 | -98.31 ± NA | -71.63 ± 30.130 | — | -71.33 ± 26.153 | -94.97 ± 6.004 | -61.76 ± 38.208 | — | -53.49 ± 21.065 | -53.15 ± 40.480 |
| Week 48 | — | -86.97 ± 17.571 | — | — | — | — | — | -94.15 ± NA | -60.37 ± NA |
Collected over All-cause mortality, serious adverse events (SAEs) and non-serious adverse events (non-SAEs) were collected up to Week 59. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/Placebo | 0/3 (0%) | 1/3 (33.3%) | 0/3 (0%) |
| Placebo/GSK1070806 Dose Level 4 | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | 0/11 (0%) | 1/11 (9.1%) | 6/11 (54.5%) |
| GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 | 0/27 (0%) | 0/27 (0%) | 10/27 (37%) |
| Event | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|
| Necrotising soft tissue infectionInfections and infestations | 1/3 | 0/13 | 0/2 | 0/11 | 0/8 | 0/6 | 0/1 | 0/8 | 0/27 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/3 | 0/13 | 0/2 | 0/11 | 0/8 | 0/6 | 0/1 | 0/8 | 0/27 |
| CellulitisInfections and infestations | 0/3 | 0/13 | 0/2 | 1/11 | 0/8 | 0/6 | 0/1 | 0/8 | 0/27 |
| Event | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 |
|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/13 | 0/2 | 0/11 | 0/8 | 0/6 | 1/1 | 0/8 | 1/27 |
| InfluenzaInfections and infestations | 0/3 | 0/13 | 0/2 | 1/11 | 0/8 | 2/6 | 1/1 | 1/8 | 0/27 |
| Blood fibrinogen decreasedInvestigations | 0/3 | 0/13 | 0/2 | 0/11 | 0/8 | 0/6 | 1/1 | 0/8 | 0/27 |
| Urticaria cholinergicSkin and subcutaneous tissue disorders | 0/3 | 0/13 | 0/2 | 0/11 | 0/8 | 0/6 | 1/1 | 0/8 | 0/27 |
| Ligament sprainInjury, poisoning and procedural complications | 0/3 | 0/13 | 1/2 | 0/11 | 0/8 | 0/6 | 0/1 | 0/8 | 1/27 |
| NasopharyngitisInfections and infestations | 0/3 | 2/13 | 0/2 | 4/11 | 1/8 | 0/6 | 0/1 | 2/8 | 2/27 |
| EosinophiliaBlood and lymphatic system disorders | 0/3 | 0/13 | 0/2 | 0/11 | 0/8 | 0/6 | 0/1 | 2/8 | 0/27 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/3 | 0/13 | 0/2 | 2/11 | 0/8 | 0/6 | 0/1 | 1/8 | 0/27 |
| FolliculitisInfections and infestations | 0/3 | 1/13 | 0/2 | 0/11 | 0/8 | 1/6 | 0/1 | 0/8 | 0/27 |
| Herpes zosterInfections and infestations | 0/3 | 0/13 | 0/2 | 0/11 | 0/8 | 1/6 | 0/1 | 0/8 | 1/27 |
Baseline characteristics were reported for Enrolled Analysis Set which consisted of all participants who signed the informed consent form and entered the study. Participants are included in the treatment group in which they entered the long-term extension study (Study 220723 \[NCT06447506\]).
| Age, Customized(Participants) | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| 18 to 64 years | 1 | 13 | 3 | 10 | 9 | 5 | 1 | 8 | 26 | 76 |
| >=65 to 84 years | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Sex/Gender, Customized(Participants) | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 8 | 0 | 5 | 2 | 0 | 0 | 1 | 12 | 29 |
| Male | 2 | 5 | 3 | 5 | 7 | 5 | 0 | 7 | 15 | 49 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo/Placebo | Placebo/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 1 | GSK1070806 Dose Level 1/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 2 | GSK1070806 Dose Level 2/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 3 | GSK1070806 Dose Level 3/GSK1070806 Dose Level 4 | GSK1070806 Dose Level 4/GSK1070806 Dose Level 4 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| AMERICAN INDIAN OR ALASKA NATIVE | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| ASIAN | 2 | 7 | 0 | 5 | 4 | 2 | 1 | 3 | 11 | 35 |
| BLACK OR AFRICAN AMERICAN | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 4 |
| WHITE | 1 | 4 | 1 | 2 | 5 | 2 | 0 | 3 | 13 | 31 |
| MIXED RACE | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 3 |
| NOT REPORTED | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Jun 2024 to primary completion in Jul 2025, 13 months.
Results were first posted in Jun 2026, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1070806